A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
Phase 1
Completed
- Conditions
- Influenza, Pandemic
- Interventions
- Biological: rH5 (100 µg) control - pipette - INBiological: Saline (Placebo) - pipette - INBiological: H5N1 IIV - IM
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- BlueWillow Biologics
- Target Recruit Count
- 40
- Registration Number
- NCT05397119
- Locations
- 🇺🇸
Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, United States
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults
Phase 1
Completed
- Conditions
- Anthrax
- Interventions
- Biological: Saline (Placebo) - pipette - INBiological: BioThrax (positive control) - SCBiological: Saline (Placebo) - sprayer - IN
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- BlueWillow Biologics
- Target Recruit Count
- 84
- Registration Number
- NCT04148118
- Locations
- 🇺🇸
Johnson County Clin-Trial, Lenexa, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath